A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs C2N 8E12 (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 05 Mar 2018 Planned number of patients changed from 180 to 330.
- 05 Mar 2018 Planned End Date changed from 3 Sep 2019 to 11 Jun 2020.
- 05 Mar 2018 Planned primary completion date changed from 18 May 2019 to 11 Jun 2020.